Colon Cancer Home > Erbitux Average Treatment Length

Erbitux® (cetuximab) is a drug prescribed for the treatment of cancer. Specifically, it is approved for squamous cell carcinoma of the head and neck and certain kinds of advanced colorectal cancer. The average length of treatment for Erbitux will depend on the condition being treated and how well you tolerate the drug.
 
For example, if you are receiving Erbitux in addition to radiation treatment for head and neck cancer, you will be given your first dose one week before starting radiation. Subsequent doses will be given so that the dose is complete one hour before radiation. Treatment will continue for the remainder of radiation therapy (normally six or seven weeks).
 
(Click Erbitux Dosage to learn more about how long treatment can last, the factors that will affect your dose, and how to ensure the drug's safety and effectiveness.)
 
Written by/reviewed by:
Last reviewed by: Kristi Monson, PharmD;
Last updated/reviewed:
List of references (click here):
Advertisement
Topics & Medications

Quicklinks

Related Channels

eMedTV Links
Copyright © 2006-2019 Clinaero, Inc.

eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.

This site complies with the HONcode standard for trustworthy health information:
verify here.